A study to determine post-vaccination T-cell response and its relationship to antibody responses in patients with inflammatory bowel disease on immune-modifying therapies
Latest Information Update: 28 Jul 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics; Therapeutic Use
Most Recent Events
- 28 Jul 2022 New trial record